Keeping an Eye on United Therapeutics Corp (UTHR) After Insider Trading Activity

United Therapeutics Corp’s filing revealed that its Officer PAUL MAHON acquired Company’s shares for reported $3.08 million on Jun 12 ’25. In the deal valued at $279.96 per share,11,000 shares were bought.

Then, EDGEMOND JAMES sold 12,000 shares, generating $3,904,496 in total proceeds. Upon selling the shares at $325.37, the CFO AND TREASURER now owns 8,118 shares.

Before that, EDGEMOND JAMES sold 12,000 shares. United Therapeutics Corp shares valued at $3,909,893 were divested by the CFO AND TREASURER at a price of $325.82 per share. As a result of the transaction, EDGEMOND JAMES now holds 8,118 shares, worth roughly $2.3 million.

Cantor Fitzgerald initiated its United Therapeutics Corp [UTHR] rating to an Overweight in a research note published on June 02, 2025; the price target was $405. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who decreased its forecast for the stock in late April from “an Overweight” to “an Equal weight”. BofA Securities also remained covering UTHR and has increased its forecast on April 21, 2025 with a “Neutral” recommendation from previously “an Underperform” rating. Morgan Stanley revised its rating on July 11, 2024. It rated UTHR as “an Equal-weight” which previously was an “an Overweight”.

Price Performance Review of UTHR

On Friday, United Therapeutics Corp [NASDAQ:UTHR] saw its stock fall -0.98% to $283.35. Over the last five days, the stock has lost -13.03%. United Therapeutics Corp shares have fallen nearly -19.69% since the year began. Nevertheless, the stocks have risen 2.75% over the past one year. While a 52-week high of $417.82 was reached on 02/19/25, a 52-week low of $266.98 was recorded on 04/09/25.

Levels Of Support And Resistance For UTHR Stock

The 24-hour chart illustrates a support level at 281.19, which if violated will result in even more drops to 279.04. On the upside, there is a resistance level at 286.31. A further resistance level may holdings at 289.28.

How much short interest is there in United Therapeutics Corp?

A steep rise in short interest was recorded in United Therapeutics Corp stocks on 2025-05-30, dropping by 91585.0 shares to a total of 1.88 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-30 was 1.97 million shares. There was a decline of -4.88%, which implies that there is a negative sentiment for the stock.

Most Popular

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.